Oral oncolytics represent 25% to 35% of the drugs in the oncology pipeline.1 They are patient friendly, allow patients to manage their treatment, and overall, have a less disruptive effect on patient's everyday lives.
Welcome to our first newsletter in the Conquering the Multiple Myeloma Continuum series, which focuses on adherence to oral medications in patients with multiple myeloma (MM). In this first newsletter, you will learn about some of the major causes of nonadherence that patients and their providers face.
For the past few years, much attention has been given to the development and US Food and Drug Administration (FDA) approval of targeted oral chemotherapy agents. As our knowledge of cancer and its molecular biology increases, many targeted oral chemotherapy agents have become available for use in clinical practice. The emergence of oral chemotherapy agents has provided alternative treatment options and allowed patients to receive cancer treatment in the convenience of their home. While there are many advantages to oral chemotherapy treatment, there are also many safety concerns.
Oral chemotherapeutic agents have transformed the management of cancer treatment— transitioning the primary location of care to the ambulatory setting and providing patients with a convenient, noninvasive option to manage their malignancy.